On this episode of Advances in Care, Erin Welsh is joined by Dr. Barbara Ma, a medical oncologist at NewYork-Presbyterian who leads Cellular Therapy for Solid Tumors at Weill-Cornell Medicine. Dr. Ma and her team are at the forefront of utilizing a new therapy in the treatment of metastatic melanoma called tumor-infiltrating lymphocyte therapy—or TIL therapy—which received FDA approval in 2024. Patients receiving TIL therapy have seen tumors shrink in as little as one week after their first round of treatment. Dr. Ma discusses how her team is working to optimize TIL therapy by shortening the manufacturing process and reducing treatment-related toxicity to improve the patient experience. NewYork-Presbyterian and Weill Cornell Medicine is one of only a handful of medical centers to provide TIL therapy based on the complexity of this treatment approach, and also lead new research efforts to expand its potential for treating solid tumor cancers.